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A B S T R A C T
Background
Premenstrual syndrome (PMS) is a psychological and somatic disorder of unknown aetiology, with symptoms typically including
irritability, depression, mood swings, bloating, breast tenderness and sleep disturbances. About 3% to 10% of women who experience
these symptoms may also meet criteria for premenstrual dysphoric disorder (PMDD). PMS symptoms recur during the luteal phase of
the menstrual cycle and reduce by the end of menstruation. PMS results from ovulation and may be due to ovarian steroid interactions
relating to neurotransmitter dysfunction. Premenstrual disorders have a devastating effect on women, their families and their work.
Several treatment options have been suggested for PMS, including pharmacological and surgical interventions. The treatments thought
to be most effective tend to fall into one of two categories: suppressing ovulation or correcting a speculated neuroendocrine anomaly.
Transdermal oestradiol by patch, gel or implant effectively stops ovulation and the cyclical hormonal changes which produce the
cyclical symptoms. These preparations are normally used for hormone therapy and contain lower doses of oestrogen than found in oral
contraceptive pills. A shortened seven-day course of a progestogen is required each month for endometrial protection but can reproduce
premenstrual syndrome-type symptoms in these women.
Objectives
To determine the effectiveness and safety of non-contraceptive oestrogen-containing preparations in the management of PMS.
Search methods
On 14 March 2016, we searched the following databases: the Cochrane Gynaecology and Fertility Group (CGF) Specialised Register;
Cochrane Central Register of Studies (CRSO); MEDLINE; Embase; PsycINFO; CINAHL; ClinicalTrials.gov; metaRegister of Con-
trolled trials (mRCT); and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) Search
Portal. In addition, we checked the reference lists of articles retrieved.
1Non-contraceptive oestrogen-containing preparations for controlling symptoms of premenstrual syndrome (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Selection criteria
We included published and unpublished randomized placebo or active controlled trials on the efficacy of the use of non-contraceptive
oestrogen-containing preparations in the management of premenstrual syndrome in women of reproductive age with PMS diagnosed
by at least two prospective cycles without current psychiatric disorder.
Data collection and analysis
Two review authors independently selected studies, assessed risk of bias, extracted data on premenstrual symptoms and adverse effects
and entered data into Review Manager 5 software. Where possible, intention-to-treat or modified intention-to-treat analysis was used.
Studies were pooled using a fixed-effect model, analysing cross-over trials as parallel trials. Standardised mean differences (SMDs) with
95% confidence intervals (CIs) were calculated for premenstrual symptom scores. Risk ratios (RRs) with 95% confidence intervals
(CIs) were calculated for dichotomous outcomes. The overall quality of the evidence was assessed using the GRADE working group
methods.
Main results
The search resulted in 524 potentially relevant articles. Five eligible randomized controlled trials (RCTs) were identified (305 women).
Trials using oral tablets, transdermal patches and implants were identified. No trial used gels.
One small cross-over trial (11women, effective sample size 22women considering cross-over trials) compared oral luteal-phase oestrogen
versus placebo. Data were very low quality and unsuitable for analysis, but study authors reported that the intervention was ineffective
and might aggravate the symptoms of PMS. They also reported that there were no adverse events.
Three studies compared continuous oestrogen with progestogen versus placebo (with or without progestogen). These trials were of
reasonable quality, although with a high risk of attrition bias and an unclear risk of bias due to potential carry-over effects in two cross-
over trials. Continuous oestrogen had a small to moderate positive effect on global symptom scores (SMD −0.34, 95% CI −0.59 to
−0.10, P = 0.005, 3 RCTs, 158 women, effective sample size 267 women, I² = 63%, very low quality evidence). The evidence was too
imprecise to determine if the groups differed in withdrawal rates due to adverse effects (RR 0.64, 95% CI 0.26 to 1.58, P = 0.33, 3
RCTs, 196 women, effective sample size 284 women, I² = 0%, very low quality evidence). Similarly, the evidence was very imprecise
in measures of specific adverse events, with large uncertainties around the true value of the relative risk. None of the studies reported
on long-term risks such as endometrial cancer or breast cancer.
One study compared patch dosage (100 vs 200 µg oestrogen, with progestogen in both arms) and had a high risk of performance bias,
detection bias and attrition bias. The study did not find evidence that dosage affects global symptoms but there was much uncertainty
around the effect estimate (SMD−1.55, 95% CI−8.88 to 5.78, P = 0.68, 1 RCT, 98 women, very low quality evidence). The evidence
on rates of withdrawal for adverse events was too imprecise to draw any conclusions (RR 0.70, 95% CI 0.34 to 1.46, P = 0.34, 1 RCT,
107 women, low-quality evidence). However, it appeared that the 100 µg dose might be associated with a lower overall risk of adverse
events attributed to oestrogen (RR 0.51, 95% Cl 0.26 to 0.99, P = 0.05, 1 RCT, 107 women, very low quality evidence) with a large
uncertainty around the effect estimate.
The overall quality of the evidence for all comparisons was very low, mainly due to risk of bias (specifically attrition), imprecision, and
statistical and clinical heterogeneity.
Authors’ conclusions
We found very lowquality evidence to support the effectiveness of continuous oestrogen (transdermal patches or subcutaneous implants)
plus progestogen, with a small to moderate effect size. We found very low quality evidence from a study based on 11 women to suggest
that luteal-phase oral unopposed oestrogen is probably ineffective and possibly detrimental for controlling the symptoms of PMS. A
comparison between 200 µg and 100 µg doses of continuous oestrogen was inconclusive with regard to effectiveness, but suggested
that the lower dose was less likely to cause side effects. Uncertainty remains regarding safety, as the identified studies were too small to
provide definite answers. Moreover, no included trial addressed adverse effects that might occur beyond the typical trial duration of 2-
8 months. This suggests the choice of oestrogen dose and mode of administration could be based on an individual woman’s preference
and modified according to the effectiveness and tolerability of the chosen regimen.
P L A I N L A N G U A G E S U M M A R Y
Oestrogen for premenstrual syndrome
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Review question
Oestrogen is widely used to suppress ovulation, mainly as a contraceptive. This is the first systematic review aiming to evaluate the
effectiveness and safety of non-contraceptive oestrogen-containing preparations (oral, patch, implant and gel) in controlling symptoms
of premenstrual syndrome (PMS).
Background
PMS is characterised by a range of physical, psychological and behavioural symptoms that are not due to any organic disease, and
that occur during the luteal phase (second half ) of the menstrual cycle and disappear at the onset of menstruation. It is now thought
that the condition is due to complex interactions between ovarian steroids and neurotransmitters. A clinical diagnosis requires that the
symptoms are confirmed by prospective recording for at least two menstrual cycles and that they cause substantial distress or impairment
to daily life (e.g. work, school, social activities, hobbies, interpersonal relationships).
Study characteristics
The review identified 524 potentially relevant articles. Only five randomized controlled trials met our inclusion criteria, and these
compared oestrogen with placebo in a total of 305 women who were clinically diagnosed with PMS.
Key results
We found very low quality evidence to suggest that oral unopposed oestrogen given in the luteal phase of the menstrual cycle is probably
ineffective for controlling the symptoms of PMS and may even make them worse. There was very low quality evidence to support the
effectiveness of continuous oestrogen (in the form of transdermal patches or subcutaneous implants) plus progestogen, with a small to
moderate effect size. A comparison between 200 microgram and 100 microgram doses of continuous oestrogen was inconclusive with
regard to effectiveness but suggested that the lower dose was less likely to cause side effects. Uncertainty remains regarding safety, as the
identified studies were too small to provide definite answers. Moreover, none of the included trials addressed adverse effects that might
occur beyond the typical trial duration of 2 to 8 months. This suggests the choice of oestrogen dose and mode of administration could
be based on an individual woman’s preference and modified according to the effectiveness and tolerability of the chosen regimen.
Quality of the evidence
The overall quality of the evidence for all comparisons was graded as very low, mainly due to risk of bias in the included studies,
imprecision (due to small sample sizes) and differences between the studies.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Oestrogen in combination with progestogen (sequential or continuous) compared to placebo. for controlling symptoms of premenstrual syndrome
Population: women diagnosed with symptoms of premenstrual syndrome (PMS)
Setting: community
Intervention: cont inuous oestrogen (implant or patch) plus progestogen
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with control Risk with oestrogen in
combination with pro-
gestogen
Symptom scores
over 2 to 4 menstrual
cycles1
The dif ference in the mean change f rom baseline
in symptom scores suggested a small to mod-
erate benef it in the oestrogen group (SMD 0.27
lower, 95% CI 0.47 lower to 0.07 lower)
- 158 women, ef fect ive
sample
size 267 women con-
sidering cross-over tri-
als
(3 RCTs)
⊕©©©
VERY LOW 2,3,4
Withdrawal due to ad-
verse events
over 2 to 4 menstrual
cycles1
77 per 1000 49 per 1000
(20 to 122)
RR 0.64
(0.26 to 1.58)
196 women, ef fect ive
sample
size 284 women con-
sidering cross-over tri-
als
(3 RCTs)
⊕©©©
VERY LOW 2,4,5
Specif ic adverse events
over 2 to 4 menstrual
cycles1
Two RCTs (total 206 women) assessed one or more of nine specif ic adverse events and all f indings
were inconclusive. Events assessed were bleeding, breast tenderness, headache, nausea, weight
gain, dysmenorrhoea, skin irritat ion, skin react ion and skin pigmentat ion
⊕©©©
VERY LOW 1,6
* The risk in the intervention group (and its 95% conf idence interval) is based on the mean risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; RR: Risk rat io
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GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Includes cross-over trial(s), with cross-over at 3 or 4 months
2Downgraded one level for serious risk of bias: poor report ing of methods in one study and/ or high attrit ion, includes one or
more cross-over studies with unclear risk of carry-over ef fects
3Downgraded one level for serious inconsistency: I² = 63%
4Downgraded one level for quest ionable applicability: one of the studies administered progestogen in both arms
5 Downgraded one level for serious imprecision: very few events and/ or wide conf idence intervals compatible with benef it in
one or both arms or with no clinically meaningful ef fect
6Downgraded two levels for very serious imprecision: very few events and/ or very wide conf idence intervals compatible with
benef it in one or both arms or with no clinically meaningful ef fect
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B A C K G R O U N D
Description of the condition
Premenstrual syndrome (PMS) is a disorder affecting large num-
bers of women, characterised by a set of symptoms that occur dur-
ing the second half (luteal phase) of the menstrual cycle. Symp-
toms disappear by the end of menstruation and do not recur be-
fore ovulation, giving a symptom-free interval of at least one week
in the first half (follicular phase) of the menstrual cycle. PMS is
cyclical and occurs in most menstrual cycles (O’Brien 2011). PMS
is marked by a variety of emotional, physical, and behavioural
symptoms. The symptoms typically include irritability, depres-
sion, mood swings, bloating, breast tenderness and sleep distur-
bances (Gianetto-Berruti 2002; Johnson 2004; O’Brien 2003;
Panay 2005). A severe form of PMS is known as premenstrual
dysphoria or premenstrual dysphoric disorder (PMDD) and was
previously known as late luteal phase dysphoric disorder (O’Brien
2011); it causes significant distress and interferes with normal
functioning. The symptoms of PMS and PMDD are similar but
the level of impairment is greater in PMDD. Studies have reported
that as many as 85% of menstruating women have experienced
at least one symptom of PMS (Gianetto-Berruti 2002; Johnson
2004). In about 3% to 10% of women, the symptoms have ad-
verse effects on activities of daily living and may affect their inter-
personal relationships (Gianetto-Berruti 2002; Halbreich 2003;
Johnson 2004; O’Brien 2003; Panay 2005; Smith 1995). About
1.5 million women in the United Kingdom experience such se-
vere PMS that it greatly reduces their quality of life. Studies have
demonstrated deterioration in work effectiveness and cognitive
function in women with PMS compared to women without PMS
(Johnson 2004; Panay 2005).
The precise causation or aetiology of PMS remains unclear. No
significant racial or ethnic differences have been shown to exist
(Gianetto-Berruti 2002). PMS tends to be more severe among
women aged 25 to 35 years old (Johnson 2004). There appears
to be a genetic link with PMS risk; monozygotic twins are twice
as likely to suffer from PMS as dizygotic twins (Gianetto-Berruti
2002). Similarly, daughters of affectedmothers have a 70% greater
chance of experiencing PMS than those with unaffected moth-
ers (Gianetto-Berruti 2002). Past history of depressive illness is
another significant reported risk factor for PMS (Johnson 2004;
Kaur 2004). Previous publications have variably hypothesised that
PMS may be associated with excess oestrogen, a deficiency of pro-
gesterone or changes in the ratio of oestrogen and progesterone
(Gianetto-Berruti 2002). Attempts to treat the symptoms of PMS
by addressing the ratio of oestrogen and progesterone through
administering progestogen have not demonstrated benefits (Ford
2012). It is now thought that the condition is due to complex in-
teractions between ovarian steroids and neurotransmitters (Rapkin
2007). Treatment of PMS symptoms by using selective serotonin
reuptake inhibitors (SSRIs), which alter the balance of serotonin (a
neurotransmitter), has been found effective but comes with dose-
dependent adverse effects (Marjoribanks 2013). Although much
has been written on diagnostic criteria over the past 30 years,
there is no true consensus on which technique is acceptable. A
clinical diagnosis requires symptoms to be confirmed by prospec-
tive recording for at least two menstrual cycles and that symp-
toms cause substantial distress or impairment to daily life (e.g.
work, school, social activities, hobbies, interpersonal relationships)
(ACOG 2001; O’Brien 2011). Individual studies have used id-
iosyncratic techniques, this being true particularly for older stud-
ies. Typically these methods have included visual analogue scales,
categorical scales such as Moos Menstrual Distress Questionnaire,
Calendar of Premenstrual Experiences and the Daily Record of
Severity of Problems. There remains no established consensus but
the Daily Record of Severity of Problems has been used in most
recent publications.
Description of the intervention
Oestrogen therapy has been proposed as a method for manage-
ment of PMS through its ability to suppress ovulation and the
subsequent endocrine changes of the cycle. Oestrogen can be de-
livered as oral tablets, transdermal patches, implants, vaginal pes-
saries, gels and creams. Various doses and regimens of continuous
oestrogen have been used. Because the aim is to suppress ovula-
tion, the rationale for intermittent use is not clear. The oestrogens
which have been used and studied in the management of PMS
include mainly oestradiol in the form of transdermal patches or
subcutaneous implants to suppress ovulation in controlled studies
(Green 2017). Both routes of administering oestradiol appear to
show positive effects for treating mental and physical symptoms
(Green 2017). To prevent endometrial hyperplasia, cyclical pro-
gestogens are given to ensure a regular withdrawal bleed. The po-
tential oestrogens which may suppress ovulation include natural
and synthetic oestrogens.
How the intervention might work
Thoughmany theories have been proposed, the exact pathway and
definitive aetiology of PMS is unknown (O’Brien 2003; Green
2017). PMS is probably related to ovulation as symptoms do
not occur before the onset of puberty, during pregnancy or af-
ter menopause. PMS can occur in the absence of menstruation
and it therefore can occur after hysterectomy (with ovarian con-
servation) and after endometrial ablation where ovarian function
is unaffected (ISPMD 2011). This knowledge has led to the use
of several ovulation-suppressing drugs. The nature of some of
these drugs limits their long-term use because of associated sa-
fety issues, thereby also limiting their success. For example, go-
nadotrophin-releasing hormone analogues (GnRH agonists) and
danazol have both demonstrated efficacy in alleviating several pre-
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menstrual symptoms (Green 2017). Though effective, the value of
danazol is limited because of its androgenic side effects and so it is
rarely used on a long term basis. GnRH is very effective but long-
term use is limited by consequences of the resulting oestrogen-
deficient state.
Controlled trials have demonstrated that 17-β-oestradiol com-
bined with cyclical progestogen (for regular withdrawal periods
and to prevent endometrial hyperplasia) administered as an im-
plant or patch may be effective in controlling PMS symptoms
for long-term use (Green 2017). Though oestrogen appears to be
an effective agent for treating PMS, its use may be limited in in-
dividual women by the need for progestogen in women with a
uterus and because of the subsequent progestogen PMS-like side
effects. As oestrogen-only treatment has been found to be associ-
ated with endometrial hyperplasia/cancer, progestogen therapy is
recommended for endometrial protection. The use of local pro-
gestogen (levonorgestrel-releasing intrauterine system)may reduce
the occurrence of PMS-like side effects but there are no fully pub-
lished randomized controlled trials (RCTs).We specifically exclude
studies on oral contraceptives (OCs), especially those containing
drospirenone, as this has been considered in an earlier Cochrane
Review (Lopez 2012).
Why it is important to do this review
Whilst there are several published trials of oestrogen treatment of
PMS and it is widely used, there is no existing systematic review
evaluating the therapeutic effectiveness of non-contraceptive oe-
strogen-containing preparations in the management of PMS.
O B J E C T I V E S
To determine the effectiveness and safety of non-contraceptive
oestrogen-containing preparations in the management of PMS.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomized controlled trials, either published or
unpublished. We excluded non-randomized studies (for example
studies with evidence of inadequate sequence generation such as
alternate days, patient numbers) as they are associated with a high
risk of bias. Cross-over trials were eligible if feasible data from both
phases could be included in meta-analyses.
Types of participants
Inclusion
Women in the studies had to be of reproductive age. Diagnosis of
PMS had to be confirmed by prospective recording of symptoms
for at least two menstrual cycles. Diagnosis through established
criteria as set out in theDiagnostic and Statistical Manual of Mental
Disorders (DSM-III, DSM-IV or DSM-V) was not specified so as
not to exclude older studies.
Exclusion
We excluded studies if participants had only a self-diagnosis of
PMS, were on other medication which resulted in ovulation sup-
pression, had a primary psychiatric diagnosis other than premen-
strual dysphoric disorder, or were taking any other hormone ther-
apy (i.e. other than oestrogen and progestogens). Studies with par-
ticipants already receiving psychotropic medication (e.g. selective
serotonin re-uptake inhibitors) were not excluded.
Types of interventions
We included studies which compared the effects of non-contracep-
tive oestrogen-containing preparations (with or without progesto-
gen) versus placebo or alternative treatment; and studies which
compared different dosages of oestrogen.
We included all routes of administration (e.g. oral, vaginal, trans-
dermal patch, cream, gels, intrauterine route) or dosing regimen,
provided the duration was longer than one menstrual cycle.
All combined oral contraceptive preparations (oestrogen/progesto-
gen) were excluded, as were all studies of progestogen alone.
Types of outcome measures
The following outcomes were considered in this review.
Primary outcomes
1. Effectiveness (global symptom scores assessed using a
validated prospective screening tool or by pre-defined medical
diagnostic criteria).
2. Adverse events (specific adverse effects including
withdrawals for adverse effects and abnormal uterine bleeding).
Secondary outcomes
1. Specific symptoms of PMS: psychological, physical and
functional symptoms.
2. Quality of life measures.
3. Participant satisfaction.
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Search methods for identification of studies
We looked up all published and unpublished randomized con-
trolled trials (RCTs) of non-contraceptive oestrogens versus
placebo, non-contraceptive oestrogens versus alternative treat-
ments and non-contraceptive oestrogens at different dosages. All
searches were conducted without language restriction and in con-
sultation with the Cochrane Gynaecology and Fertility Group In-
formation Specialist. We attempted to identify all relevant trials
regardless of language or publication status (published, unpub-
lished, in press and in progress).
Electronic searches
The Information Specialist searched the Cochrane Gynaecology
and Fertility (CGF) Specialised Register of Controlled Trials,
Cochrane Central Register of Studies (CRSO), MEDLINE, Em-
base, PsycINFO and CINAHL on 14 March 2016. The com-
plete search strategies for the database searches are provided in
Appendix 1, Appendix 2, Appendix 3, Appendix 4, Appendix 5
and Appendix 6. There was no restriction on language.
We searched for ongoing and unpublished studies in trial reg-
isters, such as ClinicalTrials.gov (ClinicalTrials.gov/), metaReg-
ister of Controlled trials (mRCT) (www.controlled-trials.com/
mrct/) and theWorld Health Organization (WHO) International
Clinical Trials Registry Platform (ICTRP) Search Portal (http://
apps.who.int/trialsearch/).
We searched for relevant conference abstracts on the ISI Web of
Knowledge.
Searching other resources
Handsearching of conference proceedings
Proceedings from the following main conferences were hand-
searched.
• International Federation of Fertility Societies.
• American Society for Reproductive Medicine.
• British Fertility Society.
• European Society for Human Reproduction and
Embryology.
Researchers and organizations
• We contacted individual researchers working in the field to
identify unpublished and ongoing trials.
• We also contacted the UK-based National Association for
Premenstrual Syndrome (NAPS) for relevant articles.
• We contacted the following drug and pharmaceutical
companies manufacturing oestrogen to request other published
or unpublished trials: Organon, Bayer Health Care, Janssen,
Abbott, Pfizer, ReSource Medical, Meda, Norvartis, Orion, Teva
UK and Marlborough Pharmaceuticals.
Reference lists
We also checked the reference lists of all studies identified by the
above methods and examined any systematic reviews or meta-
analyses found.
Data collection and analysis
Data collection and analysis were conducted in accordance with
guidelines set out in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011).
Selection of studies
Two authors (BN and OU) independently applied inclusion cri-
teria to all identified trials. We used the titles and abstracts of the
identified citations to exclude trials that clearly did not meet the
inclusion criteria (Figure 1). If either author judged that the trial
might be eligible for inclusion, we obtained the full paper. We
independently screened the full articles of selected trials and re-
solved any disagreements with a third author (PMSO). We gave
reasons for excluding potentially relevant trials in Characteristics
of excluded studies. We attempted to contact the authors for clar-
ification.
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Figure 1. Study flow diagram.
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The selection process was illustrated in a flow diagram according
to the PRISMA statement (Figure 1) (Moher 2009).
Data extraction and management
Two authors (BN and JHK) independently extracted the data us-
ing a pre-designed data collection form. For each of the studies, we
extracted the following data: citation, study design, methodolog-
ical criteria, inclusion and exclusion criteria, comparison group
intervention, participant characteristics, trial setting, elements of
intervention, all relevant outcomes measures, and results. Where
reports were uncertain or included only summary measures, au-
thors were contacted for clarification.
We also took note of any data that were consistently underre-
ported, and highlighted this deficit along with future research
needs. We checked whether authors had conducted an intention-
to-treat (ITT) analysis (all randomized participants should be an-
alyzed in the groups to which they were originally randomized)
or one of its modifications (modified intention-to-treat or mITT;
Abraha 2010). We calculated the percentage lost to follow-up and
reported this information. For dichotomous outcome measures,
we recorded the number of participants experiencing the event
and the number analyzed in each group. For continuous outcome
measures, we extracted the mean change from baseline, the stan-
dard deviation of the mean change, and the number of women for
each treatment group at each assessment.
Where changes from baseline were not reported, the mean, stan-
dard deviation, and the number of participants for each interven-
tion group at each point in time were extracted. If the data had
been reported using geometric means, we recorded this informa-
tion and extracted a standard deviation on a log scale.
In studies with a cross-over design, data were taken from both
periods. We contacted authors for clarification and missing or
insufficient data.
Assessment of risk of bias in included studies
Two review authors (BN and JHK) independently assessed the
included studies for risk of bias using the Cochrane ’Risk of bias’
assessment tool (Higgins 2011).
This assesses (Appendix 7):
• sequence generation;
• allocation concealment;
• blinding of participants, providers and outcome assessors;
• completeness of outcome data;
• selective outcome reporting; and
• other potential sources of bias, such as inappropriate
administration of the intervention or the risk of carry-over effects
in cross-over trials.
We presented results in both a risk of bias graph and a risk of bias
summary.We interpreted the results ofmeta-analyses in the light of
the findings with respect to risk of bias. We conducted a sensitivity
analysis based on risk of bias. We resolved any disagreements by
consensus or by discussion with a third author.
Measures of treatment effect
For dichotomous data (e.g. adverse events), we used the numbers
of events in the control and intervention groups of each study to
calculate Mantel-Haenszel risk ratios (RRs). For continuous data
(e.g. mood score), if all studies reported exactly the same outcomes
on the same scale we calculated mean differences (MDs) between
treatment groups. If similar outcomes were reported on differ-
ent scales (e.g. Moos Menstrual Distress Questionnaire (MDQ)
and Premenstrual Distress Questionnaire (PDQ)) for premen-
strual symptoms we calculated the standardized mean difference
(SMD). We reversed the direction of effect of individual studies,
if required, to ensure consistency across trials. We presented 95%
confidence intervals (CIs) for all outcomes. Where data to cal-
culate RRs or MDs were not available, we utilized the most de-
tailed numerical data available that facilitated similar analyses of
included studies (e.g. test statistics, P values). If a separate mean
for each treatment arm could not be retrieved but the difference
and within-group standard deviation were available, we used the
generic inverse-variance method in the analyses using Hedges’ g to
calculate the standardized mean difference (SMD) (Deeks 2010).
We compared the magnitude and direction of effect reported by
studies with how they are presented in the review, taking account
of legitimate differences.
SMDs were interpreted using the following rule of thumb: 0.2
represents a small effect, 0.5 a moderate effect, and 0.8 a large
effect (Higgins 2011). A moderate effect (i.e. SMD = 0.5) can be
interpreted as the smallest change that an individual person can
perceive (Norman 2003).
Unit of analysis issues
The unit of analysis was per woman.We planned that if the woman
was not the unit of randomization, such as is the case in cluster
randomized trial (general practitioners, for example, might be the
unit of randomization), adjustments for clustering would be made
following the guidelines in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011).
In trials with a cross-over design data were taken fromboth periods
and analyzed as if they were from a parallel trial (Higgins 2011
section 16.4.5). This means that each trial participant contributed
to both trial arms unless they dropped out during the second
part of the trial, and therefore each cross-over trial participant was
effectively counted as two women. This approach gives rise to a
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unit of analysis error, but is conservative in that studies are under-
weighted rather than over-weighted.
Dealing with missing data
The data were analyzed on an intention-to-treat basis as far as
possible and attempts were made to obtain missing data from the
original trialists.Where these were unobtainable, we analyzed only
the available data.
Assessment of heterogeneity
The authors considered whether the clinical and methodological
characteristics of the included studies were sufficiently similar for
meta-analysis to provide a meaningful summary. Statistical het-
erogeneity was assessed by measurement of the I² statistic. An I²
greater than 50% was taken to indicate substantial heterogeneity
(Higgins 2003). If substantial heterogeneity was detected, possible
explanations were explored in sensitivity analyses
A rough guide to interpretation of I² values is as follows (Higgins
2011).
• 0% to 40%: might not be important.
• 30% to 60%: may represent moderate heterogeneity.
• 50% to 90%: may represent substantial heterogeneity.
• 75% to 100%: considerable heterogeneity.
Assessment of reporting biases
In view of the difficulty of detecting and correcting for publication
bias and other reporting biases, the authors aimed to minimise
their potential impact by ensuring a comprehensive search for
eligible studies and by being alert for duplication of data. If there
were 10 or more studies in an analysis, we used a funnel plot
to explore the possibility of small-study effects (a tendency for
estimates of the intervention effect to be more beneficial in smaller
studies).
Data synthesis
All eligible studies were analyzed in Cochrane’s statistical software,
RevMan 2014.Of the two authors who extracted the data, the first
author entered all data into Review Manager 5 in collaboration
with a third author, and the second rechecked all entries. Authors
resolved disagreements by discussion. They provided a narrative
synthesis for all results, along with a statistical meta-analysis if pos-
sible. An increase in the probability of a particular outcome, which
may be beneficial (e.g. improvement in global symptoms’ scores)
or detrimental (e.g. adverse effects), was displayed graphically in
the meta-analyses to the right of the centre-line and a decrease in
the odds of an outcome to the left of the centre-line.
If the studies were sufficiently similar, we combined the data using
a fixed-effect model in the following comparisons.
1. Oestrogen versus placebo.
2. Oestrogen in combination with progestogen (sequential or
continuous) versus placebo.
3. Dose comparisons of oestrogen, with or without
progestogen.
Subgroup analysis and investigation of heterogeneity
Where data were available, we conducted a subgroup analysis to
determine the separate evidence within the following subgroups.
• Subgroups by route of administration of oestrogens.
• Subgroups by mode of administration (continuous versus
phasic).
• Subgroups by route of administration of co-administered
progestogens required for protection of endometrium (not for
therapeutic effects as indeed they may re-introduce PMS-like
symptoms).
If we detected substantial heterogeneity, we planned to explore
possible explanations in sensitivity analyses. We planned to take
any statistical heterogeneity into account when interpreting the
results, especially if there is any variation in the direction of effect.
Sensitivity analysis
We conducted sensitivity analyses for the primary outcomes to
determine whether the conclusions are robust to arbitrary deci-
sions made regarding the eligibility and analysis. These analyses
included consideration of whether the review conclusions would
have differed if:
1. eligibility were restricted to studies without high risk of bias;
2. a random-effects model had been adopted;
3. the summary effect measure was odds ratio (OR) rather
than RR.
Summary of findings table
A ’Summary of findings’ table was generated using GRADE-
PRO software (GRADEpro GDT 2014) and Cochrane methods
(Higgins 2011) to evaluate the overall quality of the body of evi-
dence for our main comparisons (oestrogen vs placebo and oestro-
gen plus progestogen versus placebo) for our primary review out-
comes (effectiveness and adverse events). Two review authors inde-
pendently assessed the studies, using GRADE working group cri-
teria (i.e. study limitations (risk of bias), consistency of effect, im-
precision, indirectness and publication bias) (Atkins 2004). Judge-
ments about the quality of the evidence (high, moderate, low or
very low) were justified, documented, and incorporated into re-
porting of results for each outcome.
R E S U L T S
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Description of studies
Results of the search
We prepared a PRISMA flowchart to describe how we processed
the references identified through the search results (see Figure 1)
(Moher 2009). The literature searches yielded 524 titles of po-
tentially relevant articles. After scanning titles and abstracts, we
identified a total of 10 potentially relevant articles and two au-
thors independently assessed full-text copies against the inclusion
criteria. We scanned the reference lists of these studies for further
studies, but none were found. Eventually, we excluded five studies
with reasons and five studies met the inclusion criteria.
See Characteristics of included studies and Characteristics of
excluded studies.
Included studies
Study design and setting
Five trials were eligible for inclusion. All trials had a randomized
controlled design (see Characteristics of included studies for de-
tailed information about the individual trials). Three trials used
a cross-over design (Dhar 1990; Panay 2001; Watson 1989); and
two a parallel design (Magos 1986; Smith 1995). Four of the trials
came from a single unit at King’s CollegeHospital under the direc-
tion of Prof J Studd, Consultant Obstetrician and Gynaecologist
(Magos 1986; Panay 2001; Smith 1995; Watson 1989).
All but one study reviewed were conducted in the UK. The ex-
ception was conducted in Canada (Dhar 1990).
Participants
This review was based on data from 258 participants. The mean
number of participants per trial was 65 (range 11 to 112); (see
Characteristics of included studies for breakdown per study).
Exclusion criteria varied but most of the studies excluded women
with the following characteristics.
• Women with only a self-diagnosis of PMS.
• Women who were on other medication which resulted in
ovulation suppression.
• Women with a primary psychiatric diagnosis (other than
premenstrual dysphoric disorder).
• Women who were taking any other hormone therapy (i.e.
other than oestrogen and progestogens) though women already
receiving psychotropic medication (e.g. selective serotonin re-
uptake inhibitors) were not excluded.
Interventions
Magos 1986 investigated a subcutaneous oestrogen implant with
5 mg oral norethisterone for 7 days per cycle. versus placebo with
placebo implant for 7 days per cycle.
Watson 1989 investigated oestrogen patches with 5 mg oral
norethisterone, day 19 to 26, versus placebo patches plus 5 mg
oral norethisterone, day 19 to 26.
Panay 2001 investigated 100 µg oestradiol patches with 1 mg oral
norethisterone at 17 to 28 days versus identical placebo patches
and tablets.
Smith 1995 compared different doses of oestrogen patches (100
µg versus 200 µg). In each group half of the women were allocated
to take dydrogesterone 10 mg daily from day 17 to 26 of the cycle
and half to take medroxyprogesterone acetate 5 mg daily from day
17 to 26.
Dhar 1990 investigated oral oestrogen versus placebo.
Outcomes
All studies reported global symptom scores.
Four studies reported adverse events (specific adverse effects in-
cluding withdrawals as a result of adverse effects and abnormal
uterine bleeding).
Primary outcome measures
The primary outcome measures of effectiveness used in the stud-
ies were the Moos Menstrual Distress Questionnaire (MDQ)
(Magos 1986;Watson 1989), the PremenstrualDistressQuestion-
naire (PDQ; Panay 2001; Smith 1995; Watson 1989), and a 28-
question mental and physical symptoms daily ratings scale (Dhar
1990). The MDQ and PDQ are validated scales, in contrast to
the 28-question daily ratings scale. For all three scales, a higher
score indicated more - or more severe - symptoms, in other words
a worse outcome. The studies using MDQ and PDQ could be
pooled by using standardized mean differences. One study did not
provide an SDbut did include the 10th and 90th centile of changes
in score, which were therefore used to calculate an SD (Magos
1986). Another study (Watson 1989) did not provide enough in-
formation to determine the SD, and we therefore used the pooled
SD from another included study (Panay 2001). Although Watson
1989 was a cross-over trial, the statistical analysis in the paper was
performed as for a parallel trial. Too few data were presented in the
paper to perform a re-analysis, and therefore we reported the data
in its original parallel trial form. Likewise, the modified ITT anal-
ysis reported in the statistical report accompanying Panay 2001,
which was based on all women who provided a follow-up score,
performed the analysis as for a parallel trial. The primary outcome
measure of adverse effect was the frequency of adverse effects and
abnormal laboratory tests mentioned in the publications. All stud-
ies had data in a form that allowed a pooled analysis.
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Secondary outcome measures
Secondary outcome measures of effectiveness used in the study
were psychological and physical symptoms as provided by the
MDQ, PDQ and the 28-question ratings scale subscores. For all
these scales, a higher score indicated more or more severe symp-
toms (or both), in other words a worse outcome. The outcomes
for these two symptoms were pooled by using standardized mean
differences, again using the pooled SD from one included study -
Magos 1986 - to substitute for the missing information inWatson
1989. Further secondary outcomes were a Visual Analog Scale
(VAS) of general unwellness or well-being (Magos 1986; Smith
1995), the GHQ-60 general health questionnaire (Magos 1986),
and participant satisfaction (Smith 1995). For the VAS of feeling
unwell and the GHQ-60, a higher score indicated a worse out-
come, whereas for the VAS of feeling well a higher score indicated
a better outcome.
Sources of support
Panay 2001 was supported by industry; Magos 1986 by a research
charity; and three studies provided no information on support
(Dhar 1990; Smith 1995; Watson 1989).
Excluded studies
Five studies were excluded from this review. One randomized trial
was excluded because it did not compare oestrogen treatment to
either placebo or comparator control (Domoney 2003). Three
randomized trials were excluded because they were restricted to
specific aspects of PMS instead of global symptoms (de Lignières
1986;Dennerstein 1988; Ensom2003).One randomized trial was
excluded because itmade use of oestrogen as part of a contraceptive
(Halbreich 2012).
Risk of bias in included studies
See Figure 2 and Figure 3, and Characteristics of included studies.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Random sequence generation
Magos 1986 and Smith 1995 were judged to have a low risk and
Dhar 1990, Panay 2001 and Watson 1989 to have an unclear risk
of bias, the latter because details of the randomisation method
were not supplied.
Allocation concealment
Magos 1986, Panay 2001 and Smith 1995 were judged to have a
low risk and Dhar 1990 and Watson 1989 to have an unclear risk
of this bias.
Blinding
Performance bias
Dhar 1990; Magos 1986; Panay 2001 and Watson 1989 were
judged to have a low risk and Smith 1995 to have a high risk of
this bias.
Detection bias
Dhar 1990; Magos 1986; Panay 2001 and Watson 1989 were
judged to have a low risk and Smith 1995 to have a high risk of
this bias.
Incomplete outcome data
Three of the five trials had high rates of dropout or loss to follow
up, ranging from 20% to 29% (Magos 1986; Panay 2001; Smith
1995); these were rated at high risk of attrition bias. Dhar 1990
and Watson 1989 were rated at low risk.
A potential risk of bias in cross-over trials is dropout after the first
phase, whereby the participant does not start the second treatment.
In Watson 1989, four of the five withdrawals occurred in the first
phase and therefore did not bias the results in the two arms dif-
ferentially. One woman in the active-to-placebo group withdrew
at three months because she did not want to change treatment
because of dramatic improvement. In Panay 2001, all withdrawals
but one occurred within the first phase of the trial, Therefore no
reasons were found to suspect a systematic difference between the
two trial phases due to dropout after the first phase but before the
second phase.
Selective reporting
Dhar 1990; Magos 1986; Panay 2001; Smith 1995 and Watson
1989 (all five studies) were judged to have a low risk of bias.
Other potential sources of bias
Three of the studies were cross-over trials (Watson 1989; Dhar
1990; Panay 2001). The International Society for Premenstrual
Disorders (ISPMD) Montreal Consensus agreed that randomized
trials of premenstrual disorders should ideally have a parallel design
(ISPMD 2011), suggesting these trials were not ideal. The main
risks of cross-over trials are the potential for carry-over effects from
one period to the next, and an increased risk of attrition. The issue
of carry-over effectswas not addressed in the three trial reports. The
month-by-month graphical data of the active-to-placebo group in
Watson 1989 strongly suggest that the effect of the active treatment
has disappeared in the month after the transition from active to
placebo, butwe rated the risk of bias fromcarry-over effects unclear
given that only graphical data from a single trial supports it.
Effects of interventions
See: Summary of findings for the main comparisonOestrogen
in combination with progestogen (sequential or continuous)
compared to placebo for controlling symptoms of premenstrual
syndrome; Summary of findings 2 Oestrogen compared to
placebo for controlling symptoms of premenstrual syndrome;
Summary of findings 3Dose comparison: oestrogen 100 µg patch
compared to 200 µg patch plus progestogen in both groups for
controlling symptoms of premenstrual syndrome
1. Oestrogen versus placebo
One study reported this comparison (Dhar 1990). Luteal-phase
oestrogen was compared with placebo. As the study used non-
validated scales tomeasure effectiveness and specific (psychological
and physical) symptoms of PMS, findings are reported in narrative
rather than in forest plots. The quality of the evidence for this
comparison was rated as very low (Summary of findings 2).
Primary outcomes
1.1 Effectiveness
The study authors reported that luteal-phase oestrogen had a large
negative effect on global (mental and physical) symptoms com-
pared to placebo (P < 0.01).
1.2 Adverse events
None of the 11 women withdrew from the study. The study au-
thors reported that “no significant adverse events were encoun-
tered” but did not specify what the nature of a “significant adverse
event” would be.
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Secondary outcomes
1.3 Specific symptoms of PMS: psychological, physical and
functional symptoms
1.3.1 Psychological symptoms
The study authors reported that luteal-phase oestrogenwas signifi-
cantly less effective than placebo in relieving the severity of mental
symptoms of PMS (P < 0.02).
1.3.2 Physical symptoms
The study authors reported that luteal-phase oestrogen was sig-
nificantly less effective than placebo in relieving the severity of
physical symptoms of PMS (P < 0.02).
1.4 Quality of life
This outcome was not reported.
1.5 Patient satisfaction
This outcome was not reported.
2. Oestrogen in combination with progestogen
(sequential or continuous) versus placebo.
Three studies reported this comparison. They compared continu-
ous oestrogen (as an implant or patch) with sequential placebo ver-
sus placebo. One of the studies administered progestogen in both
arms (Watson 1989). We have included this study in this compar-
ison and conducted a post hoc sensitivity analysis to see whether
inclusion of this study influenced the results. The quality of the
evidence for this comparison was rated as very low (Summary of
findings for the main comparison)
Primary outcomes
2.1 Effectiveness
Continuous oestrogen (implants and patches) had a moderately
positive effect on global symptom scores compared to placebo
(SMD−0.27, 95% CI −0.47 to−0.07, P = 0.008, 3 RCTs, 158
women, effective sample size 267 women considering cross-over
trials, I² = 63%, very low quality evidence; Analysis 1.1; Figure
4). The statistical heterogeneity between the three trials appeared
to be mainly attributable to Panay 2001, in which a low-dose
patch (100 µg) was used. When Watson 1989 was excluded from
the analysis, findings were no longer statistically significant (SMD
−0.19, 95% CI −0.40 to 0.03).
Figure 4. Forest plot of comparison: 1 Oestrogen in combination with progestogen (sequential or
continuous) versus placebo., outcome: 1.1 Symptom scores.
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2.2 Adverse events
All three studies reported withdrawals due to adverse events. Con-
fidence intervals were very wide and there were too few events
(none in one of the studies), to establish whether there was a dif-
ference between the groups (RR 0.64, 95% CI 0.26 to 1.58, P =
0.33, 3 RCTs, 196 women, effective sample size 284 women con-
sidering cross-over trials, I² = 0%, low-quality evidence; Analysis
1.2; Figure 5). Excluding Watson 1989 from the analysis did not
influence the findings.
Figure 5. Forest plot of comparison: 1 Oestrogen in combination with progestogen (sequential or
continuous) versus placebo., outcome: 1.2 Withdrawal due to adverse events.
The two studies comparing oestrogen versus placebo also reported
specific adverse events (Magos 1986; Panay 2001; Analysis 1.3).
There were too few events reported to determine whether there
was a difference between the groups.
Findings for specific events were as follows.
• Bleeding problems (RR 0.53, 95% CI 0.10 to 2.70, P =
0.45, 1 RCT, 68 women, very low quality evidence).
• Breast tenderness (RR 1.64, 95% CI 0.87 to 3.11, P = 0.13,
2 RCTs, 206 women, I² = 69%, very low quality evidence).
• Headache (RR 0.91, 95% CI 0.53 to 1.57, P = 0.74, 2
RCTs, 206 women, I² = 0%, very low quality evidence).
• Nausea (RR 1.22, 95% CI 0.55 to 2.71, P = 0.62, 2 RCTs,
206 women, I² = 0%, very low quality evidence).
• Weight gain (RR 11.65, 95% CI 0.67 to 202.74, P = 0.09,
1 RCT, 68 women, very low quality evidence).
• Dysmenorrhoea (RR 1.55, 95% CI 0.78 to 3.05, P = 0.21,
1 RCT, 138 women, very low quality evidence).
• Skin irritation (RR 1.00, 95% CI 0.39 to 2.58, P = 1.0, 1
RCT, 40 women, very low quality evidence).
• Skin reactions (RR 0.56, 95% CI 0.19 to 1.59, P = 0.27, 2
RCTs, 178 women, I² = 0%, very low quality evidence).
• Skin pigmentation (RR 11.00, 95% CI 0.65 to 186.62, P =
0.10, 1 RCT, 40 women, very low quality evidence).
Secondary outcomes
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2.3 Specific symptoms of PMS: psychological, physical and
functional symptoms
2.3.1 Psychological symptoms
Two placebo-controlled RCTs of continuous oestrogen plus pro-
gestogen (implants or patches) provided data to determine effects
on psychological symptoms (Magos 1986; Watson 1989). Treat-
ment with implants or patches was associated with a reduction
in psychological symptoms compared to treatment with placebo
(SMD−0.79, 95% Cl−1.17 to−0.40, P < 0.00007, 2 RCTs, 88
women, effective sample size 119 women considering the cross-
over trial, I² = 78%, very low quality evidence). Findings were
imprecise and compatible with an effect size ranging from small
to large (Analysis 1.4).
However, when Watson 1989 was excluded from the analysis,
findings were no longer statistically significant (SMD−0.33, 95%
CI −0.90 to 0.24).
2.3.2 Physical symptoms
Two placebo-controlled trials of continuous oestrogen plus pro-
gestogen (implants or patches) provided data to determine ef-
fects on physical symptoms (Magos 1986;Watson 1989). Physical
symptoms were lower in the oestrogen group (SMD−0.60, 95%
Cl −0.98 to −0.22, P = 0.0019, 2 RCTs, 88 women, effective
sample size 119 women considering the crossover trial, I² = 52%,
very low quality evidence). Findings were imprecise and compat-
ible with an effect size ranging from small to large (Analysis 1.5).
However, when Watson 1989 was excluded from the analysis,
findings were no longer statistically significant (SMD−0.29, 95%
CI −0.86 to 0.28).
2.4 Quality of life
One placebo-controlled trial of continuous oestrogen (implants)
reported on general quality of life (Magos 1986). There was no
conclusive evidence of difference in a VAS for feeling unwell (MD
−10.90, 95%CI−22.60 to 0.80, P = 0.07, 1 RCT, 40 women, ef-
fective sample size 68women considering thiswas a cross-over trial,
low-quality evidence) and a general health questionnaire (MD
−3.30, 95% CI −9.98 to 3.38, P = 0.33, 1 RCT, 40/68 women,
very low quality evidence) (Analysis 1.6).
2.5 Patient satisfaction
This outcome was not reported in the included studies.
3 Dose comparisons of oestrogen, 100 µg versus 200
µg, with or without progestogen
One study compared different doses of oestrogen patches (100 µg
versus 200 µg) (Smith 1995). In each group half of the women
were allocated to take dydrogesterone 10 mg daily from day 17 to
26 of the cycle and half to take medroxyprogesterone acetate 5 mg
daily from day 17. The quality of the evidence for this comparison
was rated as very low (Summary of findings 3).
Primary outcomes
3.1 Effectiveness
The evidence was too imprecise to determine whether dosage had
an effect on global symptoms (MD −1.55 on a scale of 0 to 30,
95% CI −8.88 to 5.78, P = 0.68, 1 RCT, 98 women, very low
quality evidence) (Analysis 2.1).
3.2 Adverse events
The evidence was too imprecise to determine whether there was a
difference between the two patch dosages in withdrawal rates for
adverse events (RR 0.70, 95% CI 0.34 to 1.46, P = 0.34, 1 RCT,
107 women, very low quality evidence) (Analysis 2.2).
The evidence suggested that there might be a lower overall risk
of adverse events in the 100 µg group (RR 0.51, 95% Cl 0.26 to
0.99, P = 0.05, 1 RCT, 107 women, very low quality evidence)
(Analysis 2.2). The data did not allow extraction of individual
adverse event risks by dosage.
Secondary outcomes
3.3 Specific symptoms of PMS: psychological, physical and
functional symptoms
3.3.1 Psychological symptoms
The evidence was too imprecise to determine whether there a
difference between the two dosage groups (MD −0.28, 95% CI
−1.17 to 0.61, P = 0.54, 1 RCT, 98 women, very low quality
evidence) (Analysis 2.3).
3.3.2 Physical symptoms
The evidence was too imprecise to determine whether there a
difference between the two dosage groups (MD −0.33, 95% CI
−1.17 to 0.51, P = 0.44, 1 RCT, 98 women, very low quality
evidence) (Analysis 2.3).
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3.4 Quality of life
This study used a VAS (scale 0 to 100) for feeling well to report on
general quality of life. The evidencewas too imprecise to determine
whether there a difference between the two dosage groups (MD
1.70, 95% CI −19.43 to 22.83, P = 0.87, 1 RCT, 98 women,
very low quality evidence) (Analysis 2.4).
3.5 Patient satisfaction
The evidence was too imprecise to determine whether there a
difference in satisfaction rates between the two dosage groups (RR
1.19, 95% CI 0.85 to 1.68, P = 0.32, 1 RCT, 107 women, very
low quality evidence) (Analysis 2.5).
Other analyses
Subgroup analyses
Our planned subgroup analyses were not possible due to lack of
data.
Sensitivity analyses
Restricting eligibility to studies without high risk of bias
All five included studies had at least one item with a high risk of
bias or multiple items with an unknown risk. Restricting eligibility
to studies without an item with high risk of bias was therefore
impossible.
The three RCTs comprising the analysis of implants or patches
had substantial heterogeneity (I² = 54%), mainly due to one RCT
(Panay 2001). Restricting the analyses toMagos 1986 andWatson
1989, the two RCTs that did not show substantial heterogeneity,
increased the overall effect size of oestrogen implants or patches,
but otherwise did not appreciably change the main findings for
the primary outcome.
Adopting a random-effects model
Pooling of studieswas only used for evaluating implants or patches.
Use of a random-effects model rather than a fixed-effect model to
pool the three RCTs did not appreciably change themain findings.
Using OR rather than RR as a summary measure
Use of odds ratios (ORs) instead of risk ratios (RRs) did not affect
the results other than the obvious difference in value between the
OR and RR.
Funnel plot
There were too few studies to produce a funnel plot.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Oestrogen compared to placebo for controlling symptoms of premenstrual syndrome
Population: women diagnosed with symptoms of premenstrual syndrome (PMS)
Setting: community
Intervention: luteal-phase oestrogen
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with oestrogen
Global symptoms of
PMS
over 3 menstrual cycles
1
The study authors reported that luteal-phase
oestrogen had a large negat ive ef fect on over-
all symptoms compared to placebo (P < 0.01)
- 11 women, ef fect ive
sample size 22 women
considering this was a
cross-over trial (1 RCT)
⊕©©©
VERY LOW 2,3
Adverse events:
withdrawal due to ad-
verse events
over 3 menstrual cycles
1
No withdrawals occurred in either arm - 11 women, ef fect ive
sample size 22 women
considering this was a
cross-over trial (1 RCT)
⊕©©©
VERY LOW 2,3
Specif ic adverse events
over 3 menstrual cycles
1
The study authors reported that ‘‘no signif icant
adverse events were encountered’’
- 11 women,ef fect ive
sample size 22
women considering this
was a cross-over trial (1
RCT)
⊕©©©
VERY LOW 2,3
* The risk in the intervention group (and its 95% conf idence interval) is based on the mean risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io
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GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Cross-over study with 11 women, but analyzed as a parallel t rial (hence 22 part icipants). Women had 3 cycles in each arm.
2 Downgraded two levels for very serious risk of bias: poor report ing of methods, no data suitable for analysis as used non-
validated scales
3 Downgraded two levels for very serious imprecision: t iny sample size (but no further downgrading possible)
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Dose comparison: oestrogen 100 µg patch compared to 200 µg patch plus progestogen in both groups for controlling symptoms of premenstrual syndrome
Population: women diagnosed with symptoms of premenstrual syndrome (PMS)
Setting: community
Intervention: oestrogen 100 µg patch plus progestogen
Comparison: oestrogen 200 µg patch plus progestogen
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with 200 µg patch
plus progestogen
Risk with oestrogen
100 µg patch plus pro-
gestogen
Symptoms score: Pre-
menstrual Daily Ques-
t ionnaire (PDQ)
Scale f rom 0 to 30, with
a higher score indicat-
ing a worse outcome
over 8 months follow up
The dif ference in the change f rom baseline in
the PDQ score was too imprecise to determ ine
whether dosage had an ef fect on global symp-
toms (MD 1.55 lower, 95% CI 8.88 lower to 5.78
higher)
- 98
(1 RCT)
⊕©©©
VERY LOW 12
Adverse events - with-
drawal rates
over 8 months’ follow-
up
255 per 1000 178 per 1000
(87 to 372)
RR 0.70
(0.34 to 1.46)
107
(1 RCT)
⊕©©©
VERY LOW 12
Adverse events - spe-
cif ic side ef fects at-
tributed to oestrogen
over 8 months’ follow-
up
353 per 1000 180 per 1000
(92 to 349)
RR 0.51
(0.26 to 0.99)
107
(1 RCT)
⊕©©©
VERY LOW 12
* The risk in the intervention group (and its 95% conf idence interval) is based on the mean risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; RR: Risk rat io
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GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded two levels for very serious risk of bias: unblinded, high attrit ion
2 Downgraded two levels for very serious imprecision: wide conf idence intervals consistent with benef it in one or both arms
or with no clinically meaningful ef fect f rom the intervent ion (however no further downgrading possible)
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D I S C U S S I O N
Summary of main results
Effectiveness of oestrogen
This review found one small cross-over study (n = 11) that com-
pared oral luteal-phase oestrogen versus placebo. Data were very
low quality and unsuitable for analysis, but study authors re-
ported that the intervention was ineffective and might aggravate
the symptoms of PMS.
This review found some very low quality evidence that continu-
ous oestrogen combined with progestogen improves global symp-
toms compared to placebo. The pooled SMD for the effect of con-
tinuous oestrogen (patch or implant) on the symptoms of PMS
favoured oestrogen over placebo. This applies both to global symp-
toms and specific symptoms. The overall effect size was small to
medium (SMD = 0.34). No evidence was found that quality of life
differed between women using continuous oestrogen or placebo.
Finally, one study was found investigating the effect of oestrogen
dosage (100 µg vs 200 µg). Data were of very low quality, and
there was insufficient evidence to determine whether dosage af-
fected global or specific PMS symptoms, quality of life or patient
satisfaction.
Adverse Events
The one trial on oral luteal-phase oestrogen found no adverse
effects, but the quality of evidence was very low due to the very
small number of women studied (n = 11).
The four trials on continuous oestrogen combined with progesto-
gen reported a wide range of side effects. There was insufficient
evidence to determine a difference in adverse event rates between
oestrogen (implant or patch) plus progestogen and placebo. How-
ever, the quality of evidence was very low, mainly due to the small
sample size and a lack of long-term follow-up.
The evidence suggesting that oestrogen patch dose may affect ad-
verse effect rates was also of very low quality. The trial comparing
100 µg versus 200 µg oestrogen patches found a lower overall risk
of adverse effects in the lower-dose group.
Overall completeness and applicability of
evidence
There have been no further published studies since 2001, perhaps
because clinicians who prescribe oestrogen think that sufficient ev-
idence for the effectiveness of oestrogen is already available. How-
ever, a more important reason may be that the pharmaceutical in-
dustry sees insufficient commercial potential, particularly outside
the UK. Ideally, a large multicentre study should be conducted
based on up-to-date diagnostic criteria using validated quantifica-
tion methods.
Very low quality evidence suggested that oral luteal-phase oestro-
gen was ineffective (or even harmful) whereas continuous oestro-
gen plus progestogen was effective. A regimen of oestrogen with-
out progestogen can only be sustained by administering oestrogen
periodically, during the luteal phase. Luteal phase delivery of oe-
strogen will however not suppress ovulation, which may explain
whywomenusing oral luteal-phase oestrogen did not report a ben-
eficial effect on PMS symptoms. On the other hand, if oestrogen
is to be administered continuously, progestogen must be added to
protect the endometrium.
All four trials of oestrogen plus progestogen alluded to the possible
negative effects of oral progestogen, which was used in the trials
to protect the endometrium but can cause PMS-like side effects,
reducing treatment efficacy. Indeed, we noted withdrawals from
trials due to the side effects of oral progestogen. Unfortunately
none of the studies systematically evaluated these side effects, even
though they are commonly encountered in clinical practice. In an
attempt to overcome the PMS-like side effects, Panay 2001 used a
lower dose (1 mg instead of the usual 5 mg) of oral norethisterone
than the dose used in the other two trials of continuous oestrogen
(Magos 1986;Watson 1989).However, the lowheterogeneitywith
respect to adverse effects in these three RCTs suggests that this
strategy may not influence the rate of adverse effects and therefore
no evidence of its success was found.
Interestingly, when oestrogen is used in hormone therapy (HT),
progestogens are normally prescribed for 10 to 14 days eachmonth
to protect the endometrium. However, a Cochrane Review con-
cluded that smaller doses of progestogens during HTmay provide
adequate protectionof the endometrium (Roberts 2014).One trial
of continuous oestrogen in this review (Panay 2001) prescribed
the normal duration of 10 days’ progestogen but Magos 1986 and
Watson 1989 prescribed only 7 to 8 days of progestogen. Whether
or not such differences in duration of progestogens will affect the
risk of endometrial hyperplasia or the risk of other adverse side
effects is unknown. Clearly, further research should be aimed at
investigating the optimal dose of progestogens in order to mini-
mize the occurrence of PMS-like symptoms while still protecting
the endometrium.
Using an intrauterine releasing system for progesterone/progesto-
gens instead of oral progestogens for endometrial protection may
overcome the problem of PMS-like side effects and is commonly
used in the clinical arena. We found one conference abstract com-
paring the twomethods (Domoney 2003). In this RCT, 37women
who all received transdermal oestradiol patches were randomized
to intrauterine progesterone (n = 18) or oral progestogen (n = 19).
None of the women in the intrauterine group dropped out due
to PMS-like side effects whereas six women in the oral group did.
This provides some evidence to suggest that use of intrauterine
progesterone reduces progestagenic PMS-like side effects, but it is
not conclusive.
We searched trial databases and contacted other researchers and
relevant drug manufacturers concerning ongoing or past unre-
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ported clinical trials of non-contraceptive oestrogen management
for ovulation suppression, and there appeared to be no unreported
or ongoing studies. We have received information from one man-
ufacturer (Bayer AG, Leverkussen, Germany), who trialled the use
of a levonorgestrel-releasing intrauterine system (LNG-IUS) for
endometrial protection during oestrogen replacement therapy in
postmenopausal women, which led to its licensing for use as the
progestogen component of hormone therapy. However, there are
no published or ongoing efficacy and safety studies concerning
the use of LNG-IUS for endometrial protection under the higher
doses required for ovulation suppression in PMS.
Future clinical trials of the efficacy or effectiveness of continuous
oestrogen should therefore include an arm comparing methods to
administer progestogen.
Quality of the evidence
The three trials comparing oestrogen plus progestogen versus
placebo were at low risk of bias in most domains, though two
had a high level of attrition. The trial comparing oestrogen ver-
sus placebo was very small (n = 11), reporting of methods was
poor and it did not use a validated measure, which meant we
could only provide a narrative review. The trial comparing two
oestrogen dosages, an open label study, was at high risk of bias
in four areas (selection, performance, detection and attrition). All
trials reported the number of participants lost to follow-up; and
for all an ITT or a modified ITT analysis was available. We had
no evidence of selective outcome reporting by any of the studies.
Finally, all four trials in this review reporting on continuous oe-
strogen (Magos 1986; Panay 2001; Smith 1995; Watson 1989),
contributing 247 of the 258 women, were from a single centre
(King’s College Hospital in London). This potentially limits the
external validity of the evidence.
The overall quality of the evidence for themainfindingswas graded
as very low using the GRADE criteria, due to serious risk of bias
(related mostly to high attrition rates), imprecision due to the
small total sample size and statistical and clinical heterogeneity (I²
= 54%) in the comparison of oestrogen plus progestogen versus
placebo.
Potential biases in the review process
Efforts were made to retrieve all eligible studies. The studies we
found were at least 15 years old, including one only reported in the
public literature as a conference abstract. To reduce the risk that we
might miss an unpublished study, we contacted all pharmaceutical
companies that produce oestrogen tablets, patches or implants for
information about unreported past or ongoing trials, They all said
there were no such trials, but we cannot exclude that unreported
past trials exist because trial databases did not exist or were in their
infancy more than 15 years ago.
A specific issue was the use of a cross-over trial design in three
studies: Panay 2001 and Watson 1989, comparing oestrogen plus
progestogen versus placebo; and the single trial comparing oe-
strogen alone versus placebo (Dhar 1990). The ISPMDMontreal
Consensus agreed that randomized trials of premenstrual disorders
should ideally have a parallel design (O’Brien 2011), suggesting
these trials were not ideal. Their main risks would be the potential
for carry-over effects from one period to the next; and an increased
risk of attrition, specifically attrition after phase 1 of the trial, pre-
venting women entering phase 2 (Watson 1989). One trial pro-
vided month-by-month graphical data, which strongly suggested
that the effect of the active treatment haddisappeared in themonth
after the transition from active to placebo (Watson 1989). We did
therefore consider 3-month results as valid endpoints for a cross-
over trial in this review, but note that the support for it is small.
Overall, we therefore considered all cross-over trials as having an
unclear risk of other bias. Dropouts and loss to follow-up occurred
in two of the three cross-over trials but almost all occurred within
phase 1 of the trials and therefore no reasons were found to sus-
pect theywould cause a systematic difference between the two trial
phases (Panay 2001; Watson 1989). Overall, we considered this
study design suitable for the current review and included data from
both periods, which we analyzed as if they were from a parallel
trial (Higgins 2011, section 16.4.5). Our main reason for doing
so was that two of the three trials did not provide sufficient data
to allow a paired analysis, which would have been the preferred
way to incorporate the data (Higgins 2011, section 16.4.4). Our
chosen method results in confidence intervals that are too wide,
with the net effect that the cross-over trial will be under-weighted
in the final analysis and clinically important heterogeneity may be
disguised (Higgins 2011 section 16.4.5). However, we believe a
correct analysis would not have affected the reasons for grading
the overall quality of the evidence as very low.
Agreements and disagreements with other
studies or reviews
All oestrogen studies have been evaluated in this review and we
identified no other systematic review of this topic.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We found very low quality evidence to support the effectiveness
of continuous oestrogen (in the form of transdermal patches or
subcutaneous implants) plus progestogen, with a small to mod-
erate effect size. We also found very low quality evidence from a
single study of 11 women to suggest that luteal-phase unopposed
oral oestrogen is probably ineffective and possibly detrimental for
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controlling the symptoms of PMS. A comparison between 200
µg and 100 µg doses of continuous oestrogen was inconclusive
with regard to effectiveness, but suggested that the lower dose was
less likely to cause side effects. Uncertainty remains regarding sa-
fety, as the identified studies were too small to provide definite
answers. Moreover, none of the included trials addressed adverse
effects that might occur beyond the typical trial duration of 2 to 8
months. This suggests the choice of oestrogen dose and mode of
administration could be based on an individual woman’s prefer-
ence and modified according to the effectiveness and tolerability
of the chosen regimen.
Implications for research
This review found very low quality evidence that continuous oe-
strogen may be an effective treatment strategy for PMS. However,
all trials comparing continuous oestrogen to placebo were pub-
lished at least 15 years before this review and may have shown
a lesser effectiveness due to unwanted progestagenic side effects.
This can perhaps be overcome by using local progestogen in the
form of an LNG-IUS or using a different type of progestogen such
as drospirenone. Further research comparing various methods of
administering progestogens may enable continuous oestrogen to
become one of the most effective treatment options for the com-
mon condition of PMS. Our review found low-quality evidence
that continuous oestrogenmay be considered effective though they
are not widely used outside the UK. New and larger randomized
clinical trials are justified, in particular to investigate the efficacy
and safety of oestrogen in combination with the currently used
forms of endometrial protection such as LNG-IUS or different
forms of progestogen. New trials should be based on established
diagnostic criteria of the International Society for the Study of Pre-
menstrual Disorders (ISPMD), include a power analysis, have a
parallel design and report full statistical information with standard
deviations for all continuous outcomes to facilitate their inclusion
in meta-analyses.
Future research should focus on:
• direct comparisons between different oestrogen
administration regimens, including their safety, tolerability and
effectiveness for overall symptoms and for specific symptom
types over long-term follow-up;
• recruiting an adequate number of participants and
providing treatment for a sufficient duration and follow up;
• developing an agent that provides endometrial protection
without regenerating premenstrual symptoms, for example
selective progesterone receptor modulators or intrauterine
progestogens; and
• studies designed according to the established diagnostic
criteria of International Society for the Study of Premenstrual
Disorders.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Dhar 1990
Methods Randomizeddouble blindplacebo-controlled cross-over trial, with cross-over at 3months
Participants 11 women with moderate to severe PMS (a cumulative rating of 50 points over the last
10 days of the luteal phase on a 69 points daily symptoms rating scale, and a cumulative
score at least twice that during days 5 to 14 of the menstrual cycle)
Interventions Luteal-phase oestrogens versus placebo
6 women given 0.625 mg premarin for 15 days before expected date of menstruation, i.
e. luteal phase
5 women given placebo pills in same manner.
Cross-over after 3 cycles.
Duration: 6 menstrual cycles divided into 3 cycles of active treatment and 3 cycles of
placebo for each participant
Outcomes • Mental and physical symptom daily rating scale
• “Significant” adverse events (without a definition of significant)
Notes Study was conducted in Canada and supported by the pharmaceutical company St.
Laurent, Montreal, Canada
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No detail provided other than that pills
were supplied “in random order”
Allocation concealment (selection bias) Unclear risk Nothing mentioned in the study about
methods of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical looking active and placebo sup-
plied by independent laboratory
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessment by patients
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients accounted for
Selective reporting (reporting bias) Low risk All expected outcomes were reported, al-
though adverse events poorly defined
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Dhar 1990 (Continued)
Other bias High risk Unclear risk of carry-over effects, data pre-
sented as percentage of average score at fol-
low-up and therefore difficult to interpret,
main outcome measure not validated
Magos 1986
Methods Randomized double blind placebo-controlled parallel trial
Participants Women aged 25 to 45 years, with regular periods and confirmed PMS on at least 1 of
the 6 clusters in the MDQ during prospective daily symptom ratings
Interventions Subcutaneous oestradiol implants versus placebo,
33 women given 100 mg subcutaneous oestradiol implant with 5 mg oral norethisterone
for 7 days per cycle
35 women given placebo implant with 5 mg placebo for 7 days per cycle
Duration: 2 consecutive cycles.
Outcomes • Daily score rating
• Visual analogue scale of feeling unwell
• General Health Questionnaire
• Withdrawal from the study and side effects (e.g. mastalgia, nausea, weight gain).
Notes Trial was conducted in the UK and sponsored by a King’s College Voluntary Research
Trust
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table
Allocation concealment (selection bias) Low risk Independent physician concealed the allo-
cation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical looking implants used, dispensed
by independent physician
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Patient-reported scores
Incomplete outcome data (attrition bias)
All outcomes
High risk 20% of patients lost to follow-up due to
incomplete data
Selective reporting (reporting bias) Low risk All expected outcomes were reported
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Magos 1986 (Continued)
Other bias Low risk All data reported, no specific reasons to sus-
pect other bias
Panay 2001
Methods Randomizeddouble blindplacebo-controlled cross-over trial, with cross-over at 4months
Participants Women with a history of PMS longer than 12 months’ duration, and confirmed from
prospective symptom diaries (PDQ)
Interventions Oestradiol patches versus placebo
100 µg oestradiol patches with 1 mg oral norethisterone 17 to 28 days with identical
placebo patches and tablets
Duration: 8 months with cross-over at 4 months. 47 women randomized to active-first,
and 45 women randomized to placebo-first
Outcomes • PDQ
• Adverse events (e.g. headache, dysmenorrhoea, breast pain)
Notes Results of this trial, based on a per protocol analysis, have been published in abstract
form (Panay 2001). However, Dr Panay supplied the full statistical analysis of the trial
to us for the purpose of this review. This full analysis includes a modified intention-to-
treat analysis. This mITT analysis was based on the 74 women (39 in the active-first and
35 in the placebo-first arm) for whom at least one assessment was available and was used
to determine the effectiveness statistics reported in this review. The analysis of specific
adverse effects was based on the 69 women (36 in the active-first and 33 in the placebo-
first arm) who provided this information. The trial was conducted in the UK, sponsored
by a pharmaceutical company
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomization performed outside study
centre
Allocation concealment (selection bias) Low risk Allocation performed remotely and size of
randomization block withheld from inves-
tigators
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical looking patches and tablets were
used.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Patient-reported scores
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Panay 2001 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Published abstract reported 41% dropout
and 10% lost to follow-up. However, the
intention-to-treat analysis provided to the
review authors was based on 10% dropout
and 10% loss to follow-up
Selective reporting (reporting bias) Low risk All expected outcomes were reported
Other bias Unclear risk Risk of carry-over effects
Smith 1995
Methods Randomized active controlled parallel trial
Participants Women diagnosed with PMS and who showed a statistically significant PMS trend in 3
or more symptoms on a daily symptoms rating scale (PDQ) kept prospectively for a 4
to 8 week period of time
Interventions 100 µg versus 200 µg transdermal oestradiol patches
56 women were allocated to treatment with estraderm TTS 100 µg twice weekly con-
tinuously (El00 group),
56 women to treatment with Estraderm TTS 200 µg twice weekly continuously (E200
group)
In both the El00 and E200 groups half of the women were allocated to take dydroges-
terone 10 mg daily from day 17 to 26 of the cycle and half to take medroxyprogesterone
acetate 5 mg daily from day 17 to 26
Duration: follow-up visits were scheduled at the end of the 4th and 8th months of
treatment
Outcomes • Symptom score
• VAS for pain score
• Drop-outs
• Adverse effects (e.g. skin irritation, menstruation problems, bloating)
• Participants’ satisfaction
• Serum oestradiol levels
Notes Trial conducted in the UK, funding source unknown.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details provided on implementation of
envelope method
Allocation concealment (selection bias) Low risk Opaque sealed envelope
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Smith 1995 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded trial
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Non-blinded trial
Incomplete outcome data (attrition bias)
All outcomes
High risk 21% dropout and 8% lost to follow-up
Selective reporting (reporting bias) Low risk All expected outcomes were reported
Other bias Low risk No specific reasons to suspect other bias
Watson 1989
Methods Randomized double blind placebo-controlled cross-over trial, cross-over at 3 months
Participants Women with severe PMS characterised by a significant positive and negative trend on at
least 3 of the symptoms on a prospectively kept daily rating scale (PDQ)
Interventions Oestradiol patches versus placebo,
20 women given 100 µg Oestradiol patch with 5 mg oral norethisterone day 19 to 26
20 women given placebo patch with 5 mg oral norethisterone day 19 to 26
Cross-over of groups at 3 months
Duration: 6 months divided into 3 months’ active treatment and 3 months’ placebo for
each participant
Outcomes • Moos Menstrual Distress Questionnaire
• Withdrawal due to adverse effects
• Adverse events (e.g. skin reactions, skin pigmentation)
Notes Trial conducted in the UK, funding source unknown
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details on randomization method pro-
vided
Allocation concealment (selection bias) Unclear risk No details on concealment method pro-
vided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo and active treatment looked iden-
tical
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Watson 1989 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Patient-reported outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk 12.5% of patients withdrew
Selective reporting (reporting bias) Low risk All expected outcomes were reported
Other bias Unclear risk Risk of carry-over effects
MDQ = Menstrual distress questionnaire
PDQ = Premenstrual distress questionnaire
PMS = Premenstrual syndrome
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
de Lignières 1986 Study addresses effect on migraine, not on global symptoms
Dennerstein 1988 Study addresses effect on migraine, not on global symptoms
Domoney 2003 Study does not include placebo or oestrogen comparator
Ensom 2003 Study addresses effect on asthma not on global symptoms
Halbreich 2012 Study uses oestrogen as part of oral contraceptive
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D A T A A N D A N A L Y S E S
Comparison 1. Oestrogen in combination with progestogen (sequential or continuous) versus placebo.
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptom scores 3 267 Std. Mean Difference (Fixed, 95% CI) -0.27 [-0.47, -0.07]
1.1 E+P versus placebo 2 196 Std. Mean Difference (Fixed, 95% CI) -0.19 [-0.40, 0.03]
1.2 E+P versus placebo +P 1 71 Std. Mean Difference (Fixed, 95% CI) -0.69 [-1.18, -0.20]
2 Withdrawal due to adverse
events
3 284 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.26, 1.58]
2.1 E+P versus placebo 2 244 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.19, 1.59]
2.2 E+P versus placebo +P 1 40 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.16, 6.42]
3 Specific adverse events (E+P
versus placebo)
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Bleeding problems 1 68 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.10, 2.70]
3.2 Breast tenderness 2 206 Risk Ratio (M-H, Fixed, 95% CI) 1.64 [0.87, 3.11]
3.3 Headache 2 206 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.53, 1.57]
3.4 Nausea 2 206 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.55, 2.71]
3.5 Weight gain 1 68 Risk Ratio (M-H, Fixed, 95% CI) 11.65 [0.67, 202.74]
3.6 Dysmenorrhoea 1 138 Risk Ratio (M-H, Fixed, 95% CI) 1.55 [0.78, 3.05]
3.7 Skin irritation 1 40 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.39, 2.58]
3.8 Skin reactions 2 178 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.19, 1.59]
3.9 Skin pigmentation 1 40 Risk Ratio (M-H, Fixed, 95% CI) 11.0 [0.65, 186.62]
4 Specific symptoms of PMS:
psychological
2 119 Std. Mean Difference (Fixed, 95% CI) -0.79 [-1.17, -0.40]
4.1 E+P versus placebo 1 48 Std. Mean Difference (Fixed, 95% CI) -0.33 [-0.90, 0.24]
4.2 E+P versus placebo +P 1 71 Std. Mean Difference (Fixed, 95% CI) -1.18 [-1.71, -0.65]
5 Specific symptoms of PMS:
physical
2 119 Std. Mean Difference (Fixed, 95% CI) -0.60 [-0.98, -0.22]
5.1 E+P versus placebo 1 48 Std. Mean Difference (Fixed, 95% CI) -0.29 [-0.86, 0.28]
5.2 E+P versus placebo +P 1 71 Std. Mean Difference (Fixed, 95% CI) -0.85 [-1.36, -0.34]
6 Quality of life (E+P versus
placebo)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
6.1 VAS for feeling unwell
(change from baseline)
1 68 Mean Difference (IV, Fixed, 95% CI) -10.90 [-22.60, 0.
80]
6.2 General health
questionnaire (change from
baseline)
1 68 Mean Difference (IV, Fixed, 95% CI) -3.30 [-9.98, 3.38]
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Comparison 2. Dose comparison: oestrogen 100 µg patch vs 200 µg patch plus progestogen in both groups
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptoms score: maximum
mean daily PDQ
1 98 Mean Difference (IV, Fixed, 95% CI) -1.55 [-8.88, 5.78]
2 Adverse events 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Withdrawal rates 1 107 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.34, 1.46]
2.2 Side effects attributed to
oestrogen
1 107 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.26, 0.99]
3 Specific symptoms of PMS 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 Psychological symptoms 1 98 Mean Difference (IV, Fixed, 95% CI) -0.28 [-1.17, 0.61]
3.2 Physical symptoms 1 98 Mean Difference (IV, Fixed, 95% CI) -0.33 [-1.17, 0.51]
4 VAS Sense of wellbeing 1 98 Mean Difference (IV, Fixed, 95% CI) 1.70 [-19.43, 22.83]
5 Patient satisfaction 1 107 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [0.85, 1.68]
C O N T R I B U T I O N S O F A U T H O R S
BN developed the protocol and review; PMSO initiated the review; BN and JHK managed, extracted and analyzed the data; and JHK,
PMSO, OAU and FO reviewed and provided comments on the protocol and the full review.
D E C L A R A T I O N S O F I N T E R E S T
BN, JHK, OAU and FO have no interests to declare. PMSO has received some travel expenses, lecture fees and consultancy fees from
Bayer Women’s Health, Abbvie Pharma, Umecrine Mood and Asarina Pharma for his work related to premenstrual disorders but on
topics unrelated to the use of non-contraceptive oestrogens in PMS.
S O U R C E S O F S U P P O R T
Internal sources
• None, Other.
External sources
• None, Other.
36Non-contraceptive oestrogen-containing preparations for controlling symptoms of premenstrual syndrome (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
As a result of the time frame between publication of the original protocol and completion of the review, we have updated the Background
section to reflect the current state of the evidence in the field and the rationale for the intervention under review.
• We stated in the protocol that diagnosis of premenstrual dysphoric disorder must meet established psychiatric diagnostic criteria
(DSM-IV-TR). None of the studies is recent and therefore all predate such criteria (DSM III, IV or V). We therefore decided to drop
this requirement, so that we could include these older studies.
• We have included studies comparing different doses of oestrogen. This was not stated in the original search methods, but we felt
the question of oestrogen dosage would be clinically relevant.
• The protocol did not specify a time point at which to compare study outcomes. In the review, we used the 3-month time point
because it is the minimum recommended treatment duration for randomized controlled trials (ISPMD 2011).
• One of the studies made the comparison oestrogen plus progestogen versus placebo plus progestogen. We have included this study
in the analysis of oestrogen plus progestogen versus placebo and conducted a post hoc sensitivity analysis to see whether inclusion of
this study influenced the results.
• We planned to add a subgroup by mode of administration. However there were too few data to conduct this analysis.
• The protocol did not specify methods to assess aspects of risk of bias specific to cross-over trials. In the review, we addressed these
aspects under the heading Other potential sources of bias, in particular carry-over effects and differential dropout rates between the
two periods of the cross-over trial (Higgins 2011, section 16.4.3).
• In studies with a cross-over design, we planned to use only data from the first intervention phase after randomization. However,
not all cross-over trials we found allowed us to extract data from only the first phase. We therefore decided to analyze the data as if it
was from a parallel group trial (Higgins 2011, section 16.4.5). This is explained under Unit of analysis issues.
• In the case of dichotomous outcomes such as withdrawal rates or risks of adverse events we analyzed the treatment effect as risk
ratio (RR) instead of odds ratio (OR), mainly because very few clinicians are adept with ORs (Sackett 1996).
• We planned to use the standardized mean difference if outcomes were measured on different scales but did not specify the
method to be used if separate baseline and post-intervention scores could not be extracted. We now specify this methodology in the
section Measures of treatment effect because we were not able to extract these scores separately for all studies.
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